Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Garches – page 124

3 430 clinical trials in Garches, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Garches at a glance
3 430
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 430 trials in Garches

Open in trial search

Osteogenesis imperfecta

Not yet recruiting

Phase 2 Study of AGA2115 in Adults with Osteogenesis Imperfecta (COL1A1/COL1A2 Variants) Evaluating Bone Density

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AGA2115
  • Sponsor:Angitia Inc. Ltd.

Narcolepsy

Not yet recruiting

A Randomized Double‑Blind Placebo‑Controlled Study of TAK‑360 in Adults with Narcolepsy with Cataplexy (Type 1)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Systemic scleroderma+1

Not yet recruiting

Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Colitis ulcerative

Not yet recruiting

Safety and efficacy of stopping versus maintenance dose of filgotinib, tofacitinib and upadacitinib in adult ulcerative colitis patients in deep remission

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Assistance Publique Hopitaux De Marseille

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cardiac failure

Not yet recruiting

Effect of Acetazolamide Added to Standard Therapy on Weight Reduction and Symptom Relief in Patients with Heart Failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetazolamide
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Institut Gustave Roussy

Acute lymphocytic leukaemia

Not yet recruiting

Long‑term safety study of S68587 (allogeneic CD19 CAR T‑cells with TRAC and CD52 disruption) in patients with advanced lymphoid leukemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALLOGENEIC T CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR TARGETING CD19, WITH THE GENES TRAC AND CD52 DISRUPTED
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Rituximab versus clinic‑biological monitoring for ANCA reactivation in patients with GPA or MPA (with prednisolone)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Postoperative oxaliplatin liver‑directed chemotherapy plus drug combination in patients with resected colorectal liver metastases at high risk of recurrence

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Unicancer

Ovarian cancer

Not yet recruiting

Phase I/II Study of ubamatamab plus drug combination in patients with ovarian cancer who have poor response to first‑line chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Asso De Recherche Cancers Gynecologiques

Subarachnoid haemorrhage

Not yet recruiting

Ticagrelor versus placebo to prevent cerebral ischemia in patients with low‑grade aneurysmal subarachnoid hemorrhage

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ticagrelor
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Garches

What the registry says about research in the country

01 Neurological Disorders

Clinical trials focusing on innovative treatments for neuromuscular conditions and movement disorders, including studies on Spinal Muscular Atrophy and Myasthenia Gravis. Research examines novel drug delivery systems and therapeutic approaches for improving patient outcomes.

  • Spinal Muscular Atrophy Treatment
  • Myasthenia Gravis Management
  • Myotonic Dystrophy Research
02 Critical Care Medicine

Groundbreaking research in intensive care focusing on treating severe conditions like septic shock and immunosuppression. Studies evaluate new therapeutic approaches for improving survival rates and patient outcomes in critical care settings.

  • Sepsis Treatment Innovations
  • Immune System Support
  • Critical Care Interventions
03 Rare Diseases

Innovative clinical trials targeting rare genetic conditions including Pompe Disease and Fabry Disease. Research focuses on enzyme replacement therapies and novel treatment approaches to improve patient quality of life.

  • Enzyme Replacement Therapy
  • Genetic Disease Management
  • Pediatric Rare Disease Treatment
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.